All‐cause mortality · hospitalized, mechanically ventilated adults with confirmed SARS‐CoV‐2 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · Adults with haematological malignancies
Physical exercise showed no clear difference in mortality compared with no physical exercise (low certainty).
1 finding from 1 review
All‐cause mortality · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP leads to lower mortality compared with chemotherapy including ABVD (high certainty).
1 finding from 1 review
All‐cause mortality · participants with haematological malignancies
BMT showed no clear difference in mortality compared with PBSCT (high certainty).
1 finding from 1 review
Overall mortality · hospitalized, mechanically ventilated adults with confirmed SARS‐CoV‐2 infection
Early showed no clear difference in overall mortality compared with late tracheostomy (low certainty).
1 finding from 1 review
Overall mortality · DIC
1 finding from 1 review
Overall mortality · DIC
1 finding from 1 review
Overall mortality · DIC
1 finding from 1 review
Overall mortality · DIC
1 finding from 1 review
Overall mortality · patients with acquired SAA
First‐line allogeneic hematopoietic stem cell transplantation of… showed no clear difference in overall mortality compared with first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin (low certainty).
1 finding from 1 review
On‐study mortality · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in on‐study mortality compared with chemotherapy only (moderate certainty).
1 finding from 1 review
Mortality by day 30 · non‐hospitalised individuals with COVID‐19
1 finding from 1 review
Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality by day 60 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality by day 60 · non‐hospitalised individuals with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab showed no clear difference in mortality by day 30 compared with placebo (low certainty).
1 finding from 1 review
Mortality by day 60 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in mortality by day 30 compared with placebo (low certainty).
1 finding from 1 review
Mortality by day 90 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in mortality by day 90 compared with placebo (low certainty).
1 finding from 1 review
Mortality by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Casirivimab/imdevimab showed no clear difference in mortality by day 30 compared with usual care alone (moderate certainty).
1 finding from 1 review